anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Poor sleep and subsequent decline in mental health often occur during times of prolonged stress, such as a pandemic. Self-compassion is linked with improved sleep and better mental health, while self-criticism is linked with poorer sleep and psychological distress. Given there is little evidence of the interrelationships of these constructs, we examined whether higher self-compassion or lower levels of self-criticism can reduce psychological distress directly and indirectly via sleep during times of prolonged stress. Structural equation modelling was used to analyse two samples (N = 722, Study 1, and N = 622, Replication Study) of university students during different stages of the pandemic. An aggregate psychological distress construct was calculated using depression, anxiety and stress measures. We created models that showed insomnia symptoms mediated the relationship between self-compassion/self-criticism and psychological distress. Sleep partially mediated both relationships, and this was the strongest effect in both samples. This suggests that improving self-compassion and reducing self-criticism will improve sleep, leading to reduced psychological distress. As our findings are robust and held at two time points, future research should investigate broader demographics and differing stress responses.
The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
PURPOSE:To obtain a bathing agent providing bathing water with a pleasant aroma, coloring bathing water charmingly, especially having excellent warm bathing effects on bathing of the whole body, showing high fatigue recovery effects as a bathing agent on bathing of part of body. CONSTITUTION:This bathing agent comprises a mixture of 20-40pts.wt. fennel fruit, 5-20pts.wt. gardenia, 5-20pts.wt. Japanese peppermint and 5-20pts.wt. camomile as essential components. The bathing agent is expected to improve metabolism following betterment of warm bathing effects in bathing of the whole body. Only by simple handling such as bathing of part of body, fatigue is immediately and safely recovered without causing side effects.
The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. β 2 -adrenergic receptors (β 2 AR) act to relax airway smooth muscle and can serve to counteract hyperresponsiveness. Methods are provided for supplying β 2 AR function to cells of the lung and airway, such as smooth muscle and epithelial cells, by β 2 AR gene therapy. The β 2 AR gene, a modified β 2 AR gene, or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal or may be integrated into the subjects chromosomal DNA for expression. These methods provide for administering to a subject in need of such treatment a therapeutically effective amount of a β 2 AR gene, or pharmaceutically acceptable composition thereof, for overexpressing the β 2 AR gene. Such methods of expressing the administered β 2 AR gene in the lungs and airway provide for: (1) preventing or alleving bronchial hyperresponsiveness; (2) preventing or alleving of an airway obstructive disease, e.g., bronchial hyperreactivity, airway hyperresponsiveness, asthma or chronic obstructive pulmonary disorder (“COPD”); (3) reducing the airway resistance response to inhaled natural or synthetic bronchoconstrictors or allergens or to exercise; and (4) enhancing responsiveness (relaxation) of airway tissues to β-agonists.
This is a Phase II, open-label, single institution trial of treatment with single agent erlotinib. The purpose of the research is to determine the effects erlotinib has on the breast cancer tumors in women with metastatic hormone receptor negative and HER2-negative breast cancer. The Federal Drug Administration (FDA) has approved erlotinib, also known as Tarceva, for the treatment of locally advanced and metastatic non-small cell lung cancer.

To qualify for the trial, subjects must have histologically confirmed, incurable, locally advanced or metastatic breast cancer that is ER-negative, PR-negative, Her2/neu-negative and EGFR-positive. Subjects must have measurable disease. They must have received less than or equal to 1 chemotherapeutic agent in the metastatic setting. The target accrual is 43 subjects. Initially, 18 subjects will be accrued. If at least 3 subjects are progression-free at 4 months, accrual will continue to a maximum of 43 subjects. Subject eligibility will be evaluated during a screening period of 4 weeks. During the treatment period, subjects will receive single agent erlotinib, 150mg/day. Subjects will receive the first dose of erlotinib on Day 0, within 7 days of registration. Efficacy will be assessed by radiographic tumor assessment or photographic documentation. Safety will be assessed by the recording of adverse events and laboratory test results. Subjects with documented progressive disease will be discontinued from treatment and will be followed for survival information every 2 months until death, lost to follow-up or study termination.
Anticonvulsant Hypersensitivity Syndrome (AHS) is a rare drug induced, multiorgan syndrome which is potentially fatal and occurs in some patients taking anticonvulsant medication. It is characterized by fever, rash, lymphadenopathy, and other multiorgan pathologies, often hepatic. The mechanism is unknown. The interval between first drug exposure and symptoms is usually 2–4 weeks but has been reported in individuals receiving anticonvulsants for 3 or more months. Although up to 1 in 5 patients on Dilantin may develop cutaneous eruptions, only a small proportion will progress to AHS.

Patients at higher risk for developing AHS include black patients, patients who have a family history of or who have experienced this syndrome in the past, and immuno-suppressed patients. The syndrome is more severe in previously sensitized individuals. If a patient is diagnosed with AHS, discontinue the Dilantin and provide appropriate supportive measures.
With recent advances in neonatal intensive care, preterm infants are surviving into adulthood. Nonetheless, epidemiological data on the health status of these preterm infants have begun to reveal a worrying theme; prematurity and the supplemental oxygen therapy these infants receive after birth appear to be risk factors for kidney disease in adulthood, affecting their quality of life. As the incidence of chronic kidney disease and the survival time of preterm infants both increase, the management of the hyperoxia-induced renal disease is becoming increasingly relevant to neonatologists. The mechanism of this increased risk is currently unknown, but prematurity itself and hyperoxia exposure after birth may predispose to disease by altering the normal trajectory of kidney maturation. This article reviews altered renal reactivity due to hyperoxia, the possible mechanisms of renal injury due to hyperoxia, and the role of resveratrol in renal injury. KEY POINTS: · Premature infants commonly receive supplementary oxygen.. · Hyperoxia can cause kidney damage via signal pathways.. · We should reduce the occurrence of late sequelae..
The invention discloses an application of a peanut extract. The peanut extract is used for preparing food and medicines for preventing and treating neurodegenerative diseases. The invention also provides an application of a peanut active component in preparation of the food and medicines for preventing and treating the neurodegenerative diseases. The peanut active component is prepared by adopting the following steps: extracting whole peanuts or local parts of peanuts by using ethanol water, adsorbing by using non-polar resin, eluting by using ethyl alcohol, concentrating and drying. The invention also provides applications of the peanut extract and the peanut active component in preparation of the food and medicines for improving cognition and learning and memory capacity. The peanut extract and the peanut active component have the remarkable activity of imitating nerve growth factors, are capable of improving the cognition function of mice and playing a role in prevention and treatment of senile dementia and improvement of cognition and learning and memory capacity, and provides new idea for preparing the food and medicines for preventing and treating the neurodegenerative diseases and improving cognition and learning and memory capacity.
A system and a method for verifying, validating and otherwise managing distribution of products and medicines reduce the instances of counterfeit medicines. A pharmaceutical company typically provides medicines/products to users either directly or through representatives for the pharmaceutical company. The products have associated identifying or authentication codes that are used to authenticate the validity of the medicine/product. The system encrypts and decrypts code data employing appropriate client- and server- based applications to securely manage and print the authenticating code data. A covert identification technique, such as a special ink or a material can provide an additional level of security in authenticating the medicine to ensure it is not counterfeit. The special ink or the material can be tested locally by the user or sent to a remote location for testing to ensure accuracy of the medicine/product.
PURPOSE: A method of preparing an Aralia elata(Miq.) Seem. extract composition by extracting Aralia elata(Miq.) Seem. and then subjecting the extract to hydrolysis treatment under basic conditions is provided. Thus obtained extract has excellent alcohol absorption inhibiting effect. CONSTITUTION: The leaf, sprout, bark or skin of Aralia elata(Miq.) Seem. is ground, dried and extracted. Thereafter, the extract is subjected to hydrolysis treatment in a heating and pressure device such as an autoclave and the hydrolysate is neutralized by acid treatment. For an example, 1kg Aralia elata(Miq.) Seem. powder is extracted in 20L water for about 6hr and concentrated to produce 2,000ml of an extract having a solid content of 10%. And 500ml of the extract is added with 0.1N NaOH, heated at 120deg.C for 30min and neutralized with 0.1N HCl.
NEW MATERIAL:A polypeptide expressed by the formula or polypeptide having Met linked to the amino terminal thereof. USE:An antitumor agent. PREPARATION:For example, human TNF precursor cDNA is synthesized and linked to a suitable vector to give a plasmid containing a DNA fragment of a block constituting human TNF gene. The resultant plasmid is then linked to the downstream side of a suitable promoter to afford an expression type gene, which is further inserted into a microorganism, e.g. Escherichia coli, etc., to carry out transformation. The resultant recombinant microorganism is cultivated in a culture medium to produce and accumulate a novel physiologically active polypeptide in the culture. The obtained product is then separated from the produced culture to afford the aimed compound expressed by the formula.
Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
Infants ≤32 weeks with no indications for surfactant administration. Their clinical management will be the usual in our neonatal unit.
All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
FIELD: medicine, pharmacy. SUBSTANCE: solid medicinal form of the prolonged action releases an active substance continuously for 15 h independently of gastroenteric tract pH value. Composition has core containing metoprolol and shell and consists of a lot of globules (size is 0.25-2 mm) core of that have at least 95 wt.-% metoprolol as salt (solubility in water is 600 mg/ml at 25 C). Active substance is released at velocity 3-7 wt.-%/h. Polymeric shell is applied on each globule. Preferable globule size is 0.35-1.0 mm. Metoprolol salt can be benzoate or sorbate of metoprolol S-enantiomer. Globule content can contain metoprolol salt applied on the insoluble core made of silicon dioxide. Insoluble core made of silicon dioxide can show size 0.1-1.0 mm, preferably 0.15-0.3 mm, and to be coated with metoprolol salt. The formed globules (size is 0.35-1.0 mm) were coated with polymeric shell. Polymeric shell can be made of ethylcellulose or its mixture with hydroxypropylmethylcellulose. Medicinal form can be made as gelatin capsule filled with globules coated with polymeric shell, or as tablet made of the pressed globules with pharmaceutical additions. EFFECT: enhanced quality of medicinal form. 15 cl, 3 dwg, 1 tbl
The sampling frame will consist of adults, age 18 or older, with limited English proficiency (LEP), with an upper extremity injury or disorder, that have been referred to occupational therapy (OT) at Midwest Orthopaedics at Rush (MOR), require services that span four weeks or more, agree to use of interpreter services, agree to completing a paper and pencil survey at the end of four weeks, and agree to be interviewed after four weeks of occupational therapy services, following completion of the survey. LEP is determined by a preference to receive medical information in a non-English language. Sampling frame is four participants. The sampling frame will be purposive. As LEP individuals present for OT services they will be recruited for participation. Recruitment could happen simultaneously or in tandem.

The comparison group sampling frame will consist of adults, age 18 or older, proficient in English, with an upper extremity injury or disorder, that have been referred to OT at MOR, and require services that span four weeks or more. English proficiency is determined by use of English as preferred language. Sampling frame is four participants. For each LEP individual recruited, the following English-speaking individual will be asked to participate. When participants in each group are recruited, further recruitment will cease. The total sampling frame will be eight. Enlisting an English proficient individual following recruitment of an LEP individual ensures having equal participation in each group.

A paper and pencil survey will be administered in person at MOR after the initial occupational therapy visit and at the end of four weeks of OT services to the 4 Limited English proficient subjects and 4 English-speaking subjects, for 16 completed surveys. Completion will take place in a private room in the OT department. Subjects will self-select a 4 digit identification code that they will write in at the top of the survey. The sole purpose of the code is to match the pre-OT satisfaction survey with the post-OT satisfaction survey. No personal identification markers will be used on the surveys. Interviews will be conducted with each LEP individual following four weeks of OT services and after completion of the paper survey. No personal identification markers will be placed on the interview form. The interviews will be conducted in person at MOR, in a private room in the OT department. The primary investigator will present the open-ended questions with the assistance of Rush University Medical Center (RUMC) interpreter services. The documented data will be reviewed by the primary investigator for emerging themes that may provide insight and additional information.
Table 4. Description

Clobazam is a white or almost white, crystalline powder with a slightly bitter taste; is slightly soluble in water, sparingly soluble in ethanol, and freely soluble in methylene chloride. The melting range of clobazam is from 182ºC to 185ºC. The molecular formula is C16H13O2N2Cl and the molecular weight is 300.7.

Each clobazam tablet contains 10 mg or 20 mg of clobazam. Tablets also contain as inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch, silicon dioxide, and talc.
2-Thienylmethyl 2-imidazolinyl sulphide is prepared by adding thiophene to a cooled mixture of concentrated hydrochloric acid and formalin containing absorbed hydrogen chloride gas to give 2-chloromethyl-thiophene which is reacted with ethylenethiourea in methanol to give the hydrochloride of the above compound contaminated inter alia with 2,5-bis(2-imidazolinylmercapto)thiophene dihydrochloride.  Other salts, e.g. the acetate, propionate, phosphate, nitrate, sulphate, benzoate and butyrate, of the free base are described.ALSO:Pharmaceutical and veterinary anthelmintic compositions comprise a carrier and 2-thienylmethyl-2-imidazolinyl sulphide or an acid addition salt thereof, e.g. the hydrochloride, nitrate, sulphate, phosphate, acetate, propionate, butyrate or benzoate. The compositions may be put up into conventional pharmaceutical and veterinary forms, e.g. a tablet, capsule, bolus or drench and the active compound may also be administered in admixture with animal feeds and minerals, e.g. sodium chloride.  The recommended dose is from 5 to 50 mg./kg.
We are proposing a 4-year trial to determine if long-term blood pressure (BP) control after a pharmacist intervention requires continuation of the intervention or if a less intense strategy is equally efficacious. The intervention builds on the Chronic Care Model, recent Veteran Affairs (VA) trials, and our pharmacist interventions. This research has convincingly shown that collaborative interventions can improve BP control over 6-9 months. However, no randomized study has evaluated strategies to sustain the effect of such interventions.

The study will enroll 300 patients with uncontrolled HTN at the Iowa City Veteran Affairs Medical Center (VAMC) and an affiliated community based outpatient clinic (CBOC). All patients will receive a pharmacist intervention for 6 months that will follow VA HTN guidelines. Patients completing the intervention will then be randomized to continuation of the high intensity intervention or to a one-time patient and provider education intervention that was recently shown to be effective. The high intensity (HI) intervention will intensify medication regimens when BP deteriorates, sustain adherence, and improve monitoring to reduce adverse drug reactions. The low intensity (LI) intervention will involve usual care by patients primary care provider (PCPs) and a one-time education intervention including a letter emphasizing the importance of medication adherence and behavioral strategies to improve BP control (e.g., low-salt diets, exercise). PCPs of low intensity patients will also receive a computerized alert with treatment recommendations and links to BP guidelines.

The primary endpoint-BP-will be assessed using standard measurements at 6, 12, 18, 24, and 30 months post enrollment (24 months after randomization). The 24-month evaluation phase will determine if BP control can be sustained or improved with a continued high intensity intervention, relative to a low intensity intervention (Aim 1). All medication changes will be assessed to compare rates of medication intensification over the follow-up period (Aim 2). Finally, validated self-report adherence questionnaires will be used to compare medication adherence in the two groups and determine relationships between BP control and medication adherence (Aim 3).
The invention discloses a nanocomposite for loading an anti-tumor drug, a cancer cell membrane fusion TPE-s COF nano drug-loading system, and preparation and application thereof. The invention adopts a nano composite material loaded with an anti-tumor drug, which consists of a mercapto-containing lipophilic covalent organic framework TPE-s COF, a photo-thermal agent (gold nanoparticle) combined with mercapto on the surface of the TPE-s COF in a covalent bond manner, and the anti-tumor drug (cisplatin) loaded in the TPE-s COF. According to the invention, gold nanoparticles and exposed sulfhydryl groups in a TPE-s COF structure are combined in a covalent bond, cisplatin is loaded in the TPE-s COF, and then HepG2 cells and the nano carrier are co-cultured until fusion is realized, and M@TPE-s COF-Au@Cisplatin is formed through low-temperature shock. The invention realizes homologous targeting and specificity. The problems of lack of targeting and non-specificity of TPE-s COF materials and low efficiency of drug delivery systems are effectively solved. The novel combined therapy administration system can be used for liver cancer specific targeting and efficient chemotherapy/photo-thermal combined therapy.
Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
BACKGROUND: Organic selenium (Sel-Plex®) supplementation holds considerable promise for improving the effectiveness of fish production.
AIM: This experiment was accomplished to judge the potential benefits of Sel-Plex® nutritional additive on growth outcomes, physiological response, oxidative status, and immunity-linked gene expression in Nile tilapia (Oreochromis niloticus) fingerlings exposed to bacterial infection with Aeromonas hydrophila.
METHODS: Utilizing a basal diet of 30% protein, four experimental diets were prepared, each of which contained Sel-Plex® at concentrations of 0.0, 0.5, 1, and 2 mg/kg, respectively. Three replicates of 20 fish/treatment were used using 240 healthy Nile tilapia fingerlings. Fish were placed in 12 glass aquariums and separated into 4 groups at random. For the entire span of 8 weeks, diets were admitted to fish at a 3% rate of fish biomass/aquarium. After the feeding trial, pathogenic A. hydrophila was intraperitoneally injected into fish of each treatment, and fish were observed for 15 days to track the survival rate (SR) after the challenge.
RESULTS: Growth performance, physiological response, immunological parameters (phagocytic activity, phagocytic index, and lysozyme), and antioxidant parameters [catalase, superoxide dismutase (SOD), malondialdehyde, and glutathione peroxidase (GPx)] were noticeably improved in Sel-Plex® treated groups. Moreover, Sel-Plex® increased gene expression linked with the immune system in the liver (tumor necrosis factor-alpha and interleukin 1β), to growth (insulin-like growth factor 1 and growth hormone receptor), and antioxidants (SOD and GPx). Under pathogen-challenge conditions, the employed dietary Sel-Plex® supplementation could successfully lower fish oxidative stress, offering a potential preventive additive for Nile tilapia instead of antibiotics. On the other hand, Sel-Plex® significantly enhanced each of three intestinal morphological measurements (villus width, villus length, and crypt depth), demonstrating the greatest influence on the improvement of intestinal structure overall. In the Nile tilapia control group, the infection with A. hydrophila caused noticeable degenerative alterations in the gut, hepatopancreas, spleen, and posterior kidney. The severity of the lesion was significantly reduced and significantly improved with higher Sel-Plex® concentrations. Sel-Plex® supplemented groups had 100% SRs among the A. hydrophila-challenged groups.
CONCLUSION: It could be advised to enrich the diets of Nile tilapia fingerlings with 1-2 mg.kg-1 of Sel-Plex® to enhance growth rate, physiological response, immunological reaction, and intestinal absorptive capacity.